Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283526461> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4283526461 endingPage "S594" @default.
- W4283526461 startingPage "S594" @default.
- W4283526461 abstract "To evaluate treatment response, healthcare resource utilization, and direct costs for patients with rheumatoid arthritis (RA) initiating conventional disease-modifying antirheumatic drugs (csDMARDs) or biologics in Taiwan. A retrospective observational study using Taiwan’s National Health Insurance Research Database from 1/1/2015 to 12/31/2018 was conducted. Two mutually exclusive RA cohorts, incident csDMARDs users and incident biologic users, were identified and enrolled upon their first claim for a csDMARD or a biologic, in 2016, respectively. Response (stable or inadequate response [IR]) to csDMARDs and biologics was measured using a validated claims-based algorithm in the one-year after initiation. Healthcare resource utilization and direct costs (NT$) were for up to two years post enrollment. There were 7,570 and 1,770 RA patients newly initiating a csDMARD or biologic in 2016, respectively. After one-year, 28.4% and 70.1% of csDMARD initiators and 55.4% and 42.9% of biologic initiators were classified as stable or IR, respectively. RA-related hospital admissions, hospital days, emergency department visits, and outpatient visits were all significantly (p<0.01) higher for patients with IR compared to stable response in csDMARD initiators. Biologic initiators with IR had significantly higher (p<0.001) RA-related hospital admission and hospital days compared to stable response. Patients with a stable response had lower mean total direct costs than IR in both the csDMARD (NT$54,276 vs. NT$63,163; p=0.0346) and biologic cohorts (NT$392,279 vs. NT$409,408; p=0.0174). Total direct costs rose an average of 25.8% (driven by a 79.6% increase in medication costs) from year one to year two for csDMARD IR patients, compared to a 0.9% increase for stable patients. RA patients initiating their first csDMARD or biologic and achieving a stable response demonstrated lower healthcare resource utilization and costs, compared to those with an inadequate response." @default.
- W4283526461 created "2022-06-27" @default.
- W4283526461 creator A5013392612 @default.
- W4283526461 creator A5016885381 @default.
- W4283526461 creator A5023834264 @default.
- W4283526461 creator A5062832477 @default.
- W4283526461 creator A5065582377 @default.
- W4283526461 creator A5074884744 @default.
- W4283526461 creator A5087122518 @default.
- W4283526461 date "2022-07-01" @default.
- W4283526461 modified "2023-09-29" @default.
- W4283526461 title "RWD94 Treatment Response and Disease Burden of Patients with Rheumatoid Arthritis in Taiwan" @default.
- W4283526461 doi "https://doi.org/10.1016/j.jval.2022.04.1618" @default.
- W4283526461 hasPublicationYear "2022" @default.
- W4283526461 type Work @default.
- W4283526461 citedByCount "0" @default.
- W4283526461 crossrefType "journal-article" @default.
- W4283526461 hasAuthorship W4283526461A5013392612 @default.
- W4283526461 hasAuthorship W4283526461A5016885381 @default.
- W4283526461 hasAuthorship W4283526461A5023834264 @default.
- W4283526461 hasAuthorship W4283526461A5062832477 @default.
- W4283526461 hasAuthorship W4283526461A5065582377 @default.
- W4283526461 hasAuthorship W4283526461A5074884744 @default.
- W4283526461 hasAuthorship W4283526461A5087122518 @default.
- W4283526461 hasBestOaLocation W42835264611 @default.
- W4283526461 hasConcept C121955636 @default.
- W4283526461 hasConcept C126322002 @default.
- W4283526461 hasConcept C144133560 @default.
- W4283526461 hasConcept C160735492 @default.
- W4283526461 hasConcept C162324750 @default.
- W4283526461 hasConcept C167135981 @default.
- W4283526461 hasConcept C194828623 @default.
- W4283526461 hasConcept C23131810 @default.
- W4283526461 hasConcept C2777575956 @default.
- W4283526461 hasConcept C2779134260 @default.
- W4283526461 hasConcept C50522688 @default.
- W4283526461 hasConcept C6964187 @default.
- W4283526461 hasConcept C71924100 @default.
- W4283526461 hasConceptScore W4283526461C121955636 @default.
- W4283526461 hasConceptScore W4283526461C126322002 @default.
- W4283526461 hasConceptScore W4283526461C144133560 @default.
- W4283526461 hasConceptScore W4283526461C160735492 @default.
- W4283526461 hasConceptScore W4283526461C162324750 @default.
- W4283526461 hasConceptScore W4283526461C167135981 @default.
- W4283526461 hasConceptScore W4283526461C194828623 @default.
- W4283526461 hasConceptScore W4283526461C23131810 @default.
- W4283526461 hasConceptScore W4283526461C2777575956 @default.
- W4283526461 hasConceptScore W4283526461C2779134260 @default.
- W4283526461 hasConceptScore W4283526461C50522688 @default.
- W4283526461 hasConceptScore W4283526461C6964187 @default.
- W4283526461 hasConceptScore W4283526461C71924100 @default.
- W4283526461 hasIssue "7" @default.
- W4283526461 hasLocation W42835264611 @default.
- W4283526461 hasOpenAccess W4283526461 @default.
- W4283526461 hasPrimaryLocation W42835264611 @default.
- W4283526461 hasRelatedWork W2156283049 @default.
- W4283526461 hasRelatedWork W2316954211 @default.
- W4283526461 hasRelatedWork W2427452099 @default.
- W4283526461 hasRelatedWork W2587505484 @default.
- W4283526461 hasRelatedWork W2919119904 @default.
- W4283526461 hasRelatedWork W2994897345 @default.
- W4283526461 hasRelatedWork W2995645931 @default.
- W4283526461 hasRelatedWork W3040911544 @default.
- W4283526461 hasRelatedWork W3071226507 @default.
- W4283526461 hasRelatedWork W4245782456 @default.
- W4283526461 hasVolume "25" @default.
- W4283526461 isParatext "false" @default.
- W4283526461 isRetracted "false" @default.
- W4283526461 workType "article" @default.